RCEL has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
RCEL has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
AVITA Medical's Total Assets for the quarter that ended in Dec. 2024 was $79.71 Mil.
During the past 12 months, AVITA Medical's average Total Assets Growth Rate was 94.10% per year. During the past 3 years, the average Total Assets Growth Rate was 43.70% per year. During the past 5 years, the average Total Assets Growth Rate was 46.40% per year. During the past 10 years, the average Total Assets Growth Rate was 30.20% per year.
During the past 13 years, AVITA Medical's highest 3-Year average Total Assets Growth Rate was 919.00%. The lowest was -89.40%. And the median was -4.80%.
Total Assets is connected with ROA %. AVITA Medical's annualized ROA % for the quarter that ended in Dec. 2024 was -57.67%. Total Assets is also linked to Revenue through Asset Turnover. AVITA Medical's Asset Turnover for the quarter that ended in Dec. 2024 was 0.23.
The historical data trend for AVITA Medical's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AVITA Medical Annual Data | |||||||||||||||||||||
Trend | Jun15 | Jun16 | Jun17 | Jun18 | Jun19 | Jun20 | Jun21 | Dec22 | Dec23 | Dec24 | |||||||||||
Total Assets | Get a 7-Day Free Trial |
![]() |
![]() |
82.46 | 125.50 | 98.26 | 111.64 | 79.71 |
AVITA Medical Quarterly Data | ||||||||||||||||||||
Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | |
Total Assets | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
111.64 | 97.38 | 87.83 | 81.05 | 79.71 |
Total Assets are all the assets a company owns.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
AVITA Medical's Total Assets for the fiscal year that ended in Dec. 2024 is calculated as
Total Assets | = | Total Equity (A: Dec. 2024 ) | + | Total Liabilities (A: Dec. 2024 ) |
= | 4.499 | + | 75.212 | |
= | 79.71 |
AVITA Medical's Total Assets for the quarter that ended in Dec. 2024 is calculated as
Total Assets | = | Total Equity (Q: Dec. 2024 ) | + | Total Liabilities (Q: Dec. 2024 ) |
= | 4.499 | + | 75.212 | |
= | 79.71 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AVITA Medical (NAS:RCEL) Total Assets Explanation
Total Assets is connected with ROA %.
AVITA Medical's annualized ROA % for the quarter that ended in Dec. 2024 is
ROA % | = | Net Income (Q: Dec. 2024 ) | / | ( (Total Assets (Q: Sep. 2024 ) | + | Total Assets (Q: Dec. 2024 )) | / count ) |
= | -46.356 | / | ( (81.051 | + | 79.711) | / 2 ) | |
= | -46.356 | / | 80.381 | ||||
= | -57.67 % |
Note: The Net Income data used here is four times the quarterly (Dec. 2024) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
AVITA Medical's Asset Turnover for the quarter that ended in Dec. 2024 is
Asset Turnover | ||||||
= | Revenue (Q: Dec. 2024 ) | / | ( (Total Assets (Q: Sep. 2024 ) | + | Total Assets (Q: Dec. 2024 )) | / count ) |
= | 18.406 | / | ( (81.051 | + | 79.711) | / 2 ) |
= | 18.406 | / | 80.381 | |||
= | 0.23 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Thank you for viewing the detailed overview of AVITA Medical's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Robert Mcnamara | director | C/O LDR HOLDING CORPORATION, 13785 RESEARCH BOULEVARD, SUITE 200, AUSTIN TX 78750 |
David D O'toole | officer: CFO | 1640 MARENGO STREET, LOS ANGELES CA 90033 |
Suzanne Crowe | director | C/O AVITA MEDICAL, 28159 AVENUE STANFORD, SUITE 220, VALENCIA CA 91355 |
James Corbett | director | 2 GOODYEAR, IRVINE CA 92618 |
Jeremy Curnock Cook | director | TARGETED GENETICS CORP, 1100 OLIVE WAY STE 100, SEATTLE WA 98101 |
Donna Shiroma | officer: General Counsel | C/O AVITA MEDICAL, 28159 AVENUE STANFORD, SUITE 220, VALENCIA CA 91355 |
Cary Guy Vance | director | 800 EAST MIDDLEFIELD RD, MOUNTAIN VIEW CA 94043 |
Michael S Perry | director, officer: Chief Executive Officer | C/O BIOTRANSPLANT INC, 196 BOSTON AVE SUITE 2800, MEDFORD MA 02155 |
Jan Stern Reed | director | C/O JAN STERN REED BAXTER INTERNATIONAL, ONE BAXTER PARKWAY DF2 2W, DEERFIELD IL 60015 |
Michael Holder | officer: Chief Financial Officer | 6170 RESEARCH RD., STE 103, FRISCO TX 75034 |
Kathy M. Mcgee | officer: Chief Operating Officer | C/O AVITA MEDICAL, 28159 AVENUE STANFORD, SUITE 220, VALENCIA CA 91355 |
Sean Ekins | officer: Sr. VP of Finance | C/O AVITA MEDICAL, 28159 AVENUE STANFORD, SUITE 220, VALENCIA CA 91355 |
David Mcintyre | officer: Chief Financial Officer | SUITE 4 LEVEL 46 2 PARK STREET, SIDNEY C3 2000 |
Erin Liberto | officer: Chief Commercial Officer | C/O AVITA MEDICAL, 28159 AVENUE STANFORD, SUITE 220, VALENCIA CA 91355 |
Andrew Quick | officer: Chief Technology Officer | C/O AVITA MEDICAL, 28159 AVENUE STANFORD, SUITE 200, VALENCIA CA 91355 |
From GuruFocus
By Marketwired • 11-08-2024
By GuruFocus News • 11-08-2024
By Marketwired • 01-07-2025
By GuruFocus News • 01-01-2025
By Marketwired • 12-19-2024
By Marketwired • 12-23-2024
By Marketwired • 09-10-2024
By GuruFocus News • 02-22-2025
By GuruFocus Research • 09-14-2024
By GuruFocus News • 11-08-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.